Business
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson’s disease (PD), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or
About this update from Amneal Pharmaceuticals, Inc.
[{"type":"image","alt":"Knight Therapeutics","displaySize":"","headline":null,"caption":"Knight Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nIp9.tgiE4HLNmyfEs7DtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79}},"lazy":false},{"type":"text","content":"MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson’s disease (PD), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.","length":544,"tagName":"p"},{"type":"text","content":"CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease.","length":135,"tagName":"p"},{"type":"text","content":"In January 2024, Knight announced that it had entered into an agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal") for the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America.","length":250,"tagName":"p"},{"type":"text","content":"In July 2025, Knight announced that CREXONT® submission was accepted for review by Health Canada.","length":97,"tagName":"p"},{"type":"text","content":"“This submission of CREXONT® in Mexico demonstrates Knight’s continued execution of our strategy to expand our neurology portfolio,” said Samira Sakhia, President and Chief Executive Officer of Knight. “There is a high unmet medical need in the treatment of Parkinson’s disease, and we are confident that, with CREXONT®, we will be bringing a much-needed novel treatment option to Parkinson’s patients.”","length":403,"tagName":"p"},{"type":"text","content":"About CREXONT®","length":14,"tagName":"p"},{"type":"text","content":"CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/L...